NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

Kristina Lindemann, Dominique Berton, Jalid Sehouli, René DePont Christensen, Sevilay Altintas, Anja Ør Knudsen, Pierre-Etienne Heudel, Beyhan Ataseven, Ignace Vergote, Gabriel Lindahl, Coriolan Lebreton, Fabienne Schochter, Annika Auranen, Philippe Follana, Kristine Madsen, Frédéric Selle, Karen Stampe Petersson, Florence Joly, Elena Ioana Braicu, Mansoor Raza Mirza

Open source

DOI: 10.1016/j.ygyno.2025.06.008
Published: 2025-08
Container: Gynecologic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2025.06.008,
  title = {NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer},
  author = {Kristina Lindemann and Dominique Berton and Jalid Sehouli and René DePont Christensen and Sevilay Altintas and Anja Ør Knudsen and Pierre-Etienne Heudel and Beyhan Ataseven and Ignace Vergote and Gabriel Lindahl and Coriolan Lebreton and Fabienne Schochter and Annika Auranen and Philippe Follana and Kristine Madsen and Frédéric Selle and Karen Stampe Petersson and Florence Joly and Elena Ioana Braicu and Mansoor Raza Mirza},
  year = {2025},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2025.06.008},
  url = {https://doi.org/10.1016/j.ygyno.2025.06.008}
}

RIS

TY  - JOUR
TI  - NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer
AU  - Kristina Lindemann
AU  - Dominique Berton
AU  - Jalid Sehouli
AU  - René DePont Christensen
AU  - Sevilay Altintas
AU  - Anja Ør Knudsen
AU  - Pierre-Etienne Heudel
AU  - Beyhan Ataseven
AU  - Ignace Vergote
AU  - Gabriel Lindahl
AU  - Coriolan Lebreton
AU  - Fabienne Schochter
AU  - Annika Auranen
AU  - Philippe Follana
AU  - Kristine Madsen
AU  - Frédéric Selle
AU  - Karen Stampe Petersson
AU  - Florence Joly
AU  - Elena Ioana Braicu
AU  - Mansoor Raza Mirza
PY  - 2025
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2025.06.008
UR  - https://doi.org/10.1016/j.ygyno.2025.06.008
ER  -

APA

Lindemann, K., Berton, D., Sehouli, J., Christensen, R. D., Altintas, S., Knudsen, A. Ø., Heudel, P., Ataseven, B., Vergote, I., Lindahl, G., Lebreton, C., Schochter, F., Auranen, A., Follana, P., Madsen, K., Selle, F., Petersson, K. S., Joly, F., Braicu, E. I., & Mirza, M. R. (2025). NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2025.06.008

Source records

crossref · retrieved 2026-09-26T11:12:22.297Z